Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06495125
Title Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Emory University
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST